With recent FDA approvals of covalent drugs (e.g. Zanubrutinib, Ritlecitinib), covalent targeting is improving patient outcomes. By forming irreversible bonds with protein targets, covalent inhibitors offer enhanced potency, prolonged halflife, and the potential to address therapeutically relevant mutations or difficult-to-target proteins.